Losartan-antioxidant hybrids: Novel molecules for the prevention of hypertension-induced cardiovascular damage

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7220-7227

  García, Gonzalo ^a   Rodríguez Puyol, Manuel ^a   Alajarín, Ramón ^a   Serrano, Isabel ^a   Sánchez Alonso, Patricia ^a   Griera, Mercedes ^a   Vaquero, Juan J ^a   Rodríguez Puyol, Diego ^a   Álvarez Builla, Julio ^a   Díez Marqués, María L ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 3 (3,4 DIHYDROXYPHENYL)PROPIONIC ACID 2 BUTYL 3 [2' (2H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL] 3H IMIDAZOL 4 YL METHYL ESTER; 3 (3,4 DIHYDROXYPHENYL)PROPIONIC ACID 2 BUTYL 5 CHLORO 3 [2' (2H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL] 3H IMIDAZOL 4 YL METHYL ESTER; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; LOSARTAN; SARTAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HYPERTENSION; MALE; MESANGIUM CELL; NONHUMAN; RAT;

ALCOHOLS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CELLS, CULTURED; COLLAGEN TYPE I; ESTERS; FIBRONECTINS; HUMANS; HYPERTENSION; LOSARTAN; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 70949107280     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9003957     Document Type: Article

References (24)

1. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-656.
2. Daugherty, A.; Cassis, L. Angiotensin II-Mediated Development of Vascular Diseases. Trends Cardiovasc. Med. 2004, 14, 117-120.
3. For a recent example, see: Breschi, M. C.; Calderone, V.; Digiacomo, M.; Macchia, M.; Martelli, A.; Martinotti, E.; Minutolo, F.; Rapposelli, S.; Rossello, A.; Testai, L.; Balsano, A. New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design, Synthesis, and Biopharmacological Properties. J. Med. Chem. 2006, 49, 2628-2639.
4. Stocker, R.; Keaney, J. J. Role of Oxidative Modifications in Atherosclerosis. Physiol. Rev. 2004, 84, 1381-1478
5. Rajagopalan, S.; Meng, X. P.; Ramasamy, S.; Harrison, D. G.; Galis, Z. S. Reactive Oxygen Species Produced by Macrophage-Derived Foam Cells Regulate the Activity of Vascular Matrix Metalloproteinases in Vitro. Implications for Atherosclerotic Plaque Stability. J. Clin. Invest. 1996, 98, 2572-2579.
6. Ushio-Fukai, M.; Alexander, R. W.; Akers, M.; Yin, Q.; Fujio, Y.; Walsh, K.; Griendling, K. K. Reactive Oxygen Species Mediate the Activation of Akt/Protein Iinase B by Angiotensin II in Vascular Smooth Muscle Cells. J. Biol. Chem. 1999, 274, 22699-22704.
7. Uemura, S.; Matsushita, H.; Li, W.; Glassford, A. J.; Asagami, T.; Lee, K. H.; Harrison, D. G.; Tsao, P. S. Diabetes Mellitus Enhances Vascular Matrix Metalloproteinase Activity: Role of Oxidative Stress. Circ. Res. 2001, 88, 1291-1298.
8. Zmijewski, J. W.; Moellering, D. R.; Le Goffe, C.; Landar, A.; Ramachandran, A.; Darley-Usmar, V. M. Oxidized LDL Induces Mitochondrially Associated Reactive Oxygen/Nitrogen Species Formation in Endothelial Cells. Am. Physiol. Heart Circ. Physiol. 2005, 2, 852-861.
9. Cai, H.; Harrison, D. G. Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress. Circ. Res. 2000, 87, 840-844.
10. Li, P. F.; Dietz, R.; von Harsdorf, R. Differential Effect of Hydrogen Peroxide and Superoxide Anion on Apoptosis and Proliferation of Vascular Smooth Muscle Cells. Circulation 1997, 96, 3602-3609.
11. Locher, R.; Brandes, R. P.; Vetter, W.; Barton, M. Native LDL Induces Proliferation of Human Vascular Smooth Muscle Cells via Redox-Mediated Activation of ERK 1/2 Mitogen-Activated Protein Kinases. Hypertension 2002, 39, 645-650. (Pubitemid 34165199)
12. Okada, H.; Woodcock-Mitchell, J.; Mitchell, J.; Sakamoto, T.; Marutsuka, K.; Sobel, B. E.; Fujii, S. Induction of Plasminogen Activator Inhibitor Type 1 and Type 1 Collagen Expression in Rat Cardiac Microvascular Endothelial Cells by Interleukin-1 and Its Dependence on Oxygen-Centered Free Radicals. Circulation 1998, 97, 2175-2182. (Pubitemid 28262126)
13. Bartosz, M.; Kedziora, J.; Bartosz, G. Antioxidant and Prooxidant Properties of Captopril and Enalapril. Free Radic. Biol. Med. 1997, 23, 729-735.
14. Aslam, S.; Santha, T.; Leone, A.; Wilcox, C. Effects of Amlodipine and Valsartan on Oxidative Stress and Plasma Methylarginines in End-Stage Renal Disease Patients on Hemodialysis. Kidney Int. 2006, 70, 2109-21015. (Pubitemid 44871373)
15. Wu, T. C.; Chen, Y. H.; Leu, H. B.; Chen, Y. L.; Lin, F. Y.; Lin, S. J.; Chen, J. W. Carvedilol, a pharmacological Antioxidant, Inhibits Neointimal Matrix Metalloproteinase-2 and -9 in Experimental Atherosclerosis. Free Radic. Biol. Med. 2007, 43, 1508-15022.
16. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella, J. B., III; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, S.-E.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl) Imidazoles as Potent, Orally Active Antihypertensives. J. Med. Chem. 1991, 34, 2525-2547.
17. The antioxidant activity was carried out by using the kit "Total Antioxidant Status Assay", Miller, N. J.; Rice-Evans, C.; Davies, M. J.; Gopinathan, V.; Milner, A. A Novel Method for Measuring Antioxidant Capacity and Its Application to Monitoring the Antioxidant Status in Premature Neonates. Clin. Sci. 1993, 84, 407-412.
18. Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1-28.
19. Ardaillou, R.; Chansel, D.; Chatziantoniou, C.; Dussaule, J. C. Mesangial AT1 Receptors: Expression, Signaling, and Regulation. J. Am. Soc. Nephrol. 1999, 11, S40-46.
20. Torrecillas, G.; Boyano-Adánez, M. C.; Medina, J.; Parra, T.; Griera, M.; López Ongil, S.; Arilla, E.; Rodríguez Puyol, M.; Rodríguez Puyol, D. Role of Hydrogen Peroxide in the Contractile Response to Angiotensin II. Mol. Pharmacol. 2001, 59, 104-112.
21. Schmieder, R. E.; Hilgers, K. F.; Schlaich, M. P.; Schmidt, B. M. Renin-Angiotensin System and Cardiovascular Risk. Lancet 2007, 369, 1208-1219.
22. Poquet, L.; Clifford, M. N.; Williamson, G. Investigation of the Metabolic Fate of Dihydrocaffeic Acid. Biochem. Pharmacol. 2008, 75, 1218-1229.
23. Pérez-Rivero, G.; Ruiz-Torres, M. P.; Rivas-Elena, J. V.; Jerkic, M.; Díez-Marqués, M. L.; Lopez-Novoa, J. M.; Blasco, M. A.; Rodríguez-Puyol, D. Mice Deficient in Telomerase Activity Develop Hypertension Because of an Excess of Endothelin Production. Circulation 2006, 114, 309-317. (Pubitemid 44297097)
24. Cruz, C. I.; Ruiz-Torres, P.; del Moral, R. G.; Rodríguez-Puyol, M.; Rodríguez-Puyol, D. Age-Related Progressive Renal Fibrosis in Rats and Its Prevention with ACE Inhibitors and Taurine. Am. J. Physiol. Renal Physiol. 2000, 278, F122-129.